In particular, ALDH1A1 enables cancer progression by facilitating drug resistance and fostering resilience of tumor-initiating cells; this applies to cancers driven by RAS/NFκB, FLT3ITD, and mutant P53. This evidence concerns the gene NFKB1 and neoplasm.